Patent application number | Description | Published |
20140351793 | PRIORITIZING TEST CASES USING MULTIPLE VARIABLES - A computer identifies lines of code of a product program that have been modified after an initial test of the product program. The computer determines the overlap between lines of code that have been modified and a mapped test case. The computer determines a weighted value for the mapped test case based on two or more of, an environment of the test case, the degree of the overlap, a time the test case was last executed, a time the test case takes to execute, and a priority of a defect. The environment of the test case is configured to replicate a working environment where the product program is to be deployed and includes an operating system, a hardware configuration, and the configuration of the operating system. | 11-27-2014 |
20140359495 | GENERATING A CONTEXT FOR TRANSLATING STRINGS BASED ON ASSOCIATED APPLICATION SOURCE CODE AND MARKUP - A method for generating a context for translating strings for a graphical user interface. The method includes receiving a string to be translated and associated source code, the string identified by a unique key within the associated source code. The method includes identifying a first logical section of the associated source code corresponding to a unique key of the string. The method includes identifying one or more graphical user interface components within the identified logical section of the associated source code. The method then includes creating a mockup image presenting the one or more graphical user interface components and the string. | 12-04-2014 |
20140380279 | PRIORITIZING TEST CASES USING MULTIPLE VARIABLES - A computer identifies lines of code of a product program that have been modified after an initial test of the product program. The computer determines the overlap between lines of code that have been modified and a mapped test case. The computer determines a weighted value for the mapped test case based on two or more of, an environment of the test case, the degree of the overlap, a time the test case was last executed, a time the test case takes to execute, and a priority of a defect. The environment of the test case is configured to replicate a working environment where the product program is to be deployed and includes an operating system, a hardware configuration, and the configuration of the operating system. | 12-25-2014 |
20160085749 | GENERATING A CONTEXT FOR TRANSLATING STRINGS BASED ON ASSOCIATED APPLICATION SOURCE CODE AND MARKUP - An approach to generating a context for translating strings for a graphical user interface. The approach includes a computer receiving a string to be translated and associated source code, the string identified by a unique key within the associated source code and the associated source code is markup language. The computer identifies a first logical section of the associated source code corresponding to a unique key of the string and one or more graphical user interface components within the identified logical section of the associated source code. The computer then creates a mockup image presenting the one or more graphical user interface components and the string. The computer then labels, in the created mockup image, each of the one or more graphical user interface components and the first string of the plurality of strings, and identifies one or more additional graphical user interface components. | 03-24-2016 |
Patent application number | Description | Published |
20140245264 | Identifying Test Cases Based on Changed Test Code - An approach is provided to identify test cases based on changed test code. In the approach, test cases are compared to a current test environment that includes an instrumented software program that results in matching test cases. Matching test cases are selected based on a detection of one or more substantive changes to the current test environment. The current test environment is tested using the selected test cases. In an alternate approach, the current environment is tested with multiple test cases and code coverage metrics are retained. After the initial testing, modification of the software program results in comparing of the modification to the retained code coverage metrics whereupon a set of the test cases are selected and used to re-test the software program. | 08-28-2014 |
20150026664 | METHOD AND SYSTEM FOR AUTOMATED TEST CASE SELECTION - A computer-implemented method, computer program product, and computer system for intellectually and automatically selecting test cases for testing software that has been changed. In this invention, the automated selection of the subset of the test cases is based on determination of what software under test has been changed, what test cases have exercised these changes, what test data has been used to exercise these changes, what test environment including hardware and software configuration has been used to test these changes, and what pre-requisite test cases have been run prior to having the software under test in the correct state. | 01-22-2015 |
20150234677 | DYNAMICALLY ADJUSTING WAIT PERIODS ACCORDING TO SYSTEM PERFORMANCE - A method for dynamically adjusting an actual wait period associated with an operating system call, wherein the operating system call suspends execution of at least one thread in a plurality of threads associated with an operating environment is provided. The method may include determining a utilization factor function associated with the operating environment. The method may also include selecting at least one performance counter within a plurality of performance counters associated with the operating environment. The method may further include computing a utilization factor based on the determined utilization factor function and the selected at least one performance counter. Additionally, the method may include intercepting an operating system call, wherein the operating system call includes a requested wait period parameter. The method may also include updating the actual wait period associated with the intercepted operating system call based on the requested wait period parameter and the computed utilization factor. | 08-20-2015 |
20150269721 | AUTOMATED VALIDATION OF THE APPEARANCE OF GRAPHICAL USER INTERFACES - According to embodiments of the present invention, a first metadata defining how a user interface associated with an application under test should appear is generated using one or more computer processors. An image of the user interface associated with the application under test that is invoked during a test run is captured using one or more one or more computer processors. The captured image is converted, using one or more computer processors, into one or more of a second metadata and text. The first metadata is compared, using one or more computer processors, to the second metadata and the text. In response to the comparison resulting in a difference between the first metadata and the second metadata, the image is stored, using one or more computer processors, and an assessment request is generated using one or more computer processors. | 09-24-2015 |
20150317807 | THREE DIMENSIONAL VISUALIZATION OF BIG DATA - A method for visualization of big data using three dimensional pie charts. The method includes receiving at least a first set of data, comprising information detailing one or more subsets of values, each value having an associated time element. The method includes determining a three dimensional pie chart based on the at least first set of data, which includes at least as first layer comprising a first set of wedges and a second layer comprising a second set of wedges. The method includes displaying the three dimensional pie chart comprising at least the first layer and the second layer. | 11-05-2015 |
20150347212 | ERROR CLASSIFICATION IN A COMPUTING SYSTEM - In an approach to determining a classification of an error in a computing system, a computer receives a notification of an error during a test within a computing system. The computer then retrieves a plurality of log files created during the test from within the computing system and determines data containing one or more error categorizations. The computer determines a classification of the error, based, at least in part, on the plurality of log files and the data containing one or more error categorizations. | 12-03-2015 |
20150347923 | ERROR CLASSIFICATION IN A COMPUTING SYSTEM - In an approach to determining a classification of an error in a computing system, a computer receives a notification of an error during a test within a computing system. The computer then retrieves a plurality of log files created during the test from within the computing system and determines data containing one or more error categorizations. The computer determines a classification of the error, based, at least in part, on the plurality of log files and the data containing one or more error categorizations. | 12-03-2015 |
Patent application number | Description | Published |
20100021920 | MUTATED ABL KINASE DOMAINS - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 01-28-2010 |
Patent application number | Description | Published |
20090117641 | Mutated Abl Kinase Domains - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 05-07-2009 |
20100021921 | MUTATED ABL KINASE DOMAINS - The present invention relates to isolated polypeptides which comprise a functional kinase domain comprising the amino acid sequence of the native human Abl kinase domain or an essentially similar sequence thereof in which at least one amino acid selected from Met244, Leu248, Gly250, Glu252, Tyr253, Val256, Glu258, Phe311, Ile313, Phe317, Met318, Met351, Glu355, Glu359, Ile360, His361, Leu370, Asp381, Phe382, His396, Ser417, Glu459 and Phe486 is replaced by another amino acid, said mutated functional kinase domain being resistant to inhibition of its tyrosine kinase activity by N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(4-methyl-piperazin-1-ylmethyl)-benzamide or a salt thereof, to the use of such polypeptides to screen for compounds which inhibit the tyrosine kinase activity of such polypeptides, to nucleic acid molecules encoding such polypeptides, to recombinant vectors and host cells comprising such nucleic acid molecules and to the use of such nucleic acid molecules in the production of such polypeptides for use in screening for compounds which inhibit the tyrosine kinase activity of such polypeptides. | 01-28-2010 |
Patent application number | Description | Published |
20090276042 | Biological Polysiloxanes - The present invention relates to a macromonomer having a polydimethylsiloxane backbone that has a mol % dimethyl siloxanes, b mol % siloxanes substituted with -K-RIM, c mol % siloxanes substituted with -K-RIM-Z and d mol % siloxanes substituted with -L-Z, and in which the terminal siloxane groups are tri-substituted with R, wherein RIM is a refractive index modifying group; Z is a free radically polymerisable group; K is a spacer group; L is optional and is a spacer group; each R is independently selected from an RIM, a lower alkyl group, hydrogen or Z; and a is a molar percentage of the macromonomer which is in the range of from 0 to 95 mol %; b is a molar percentage of the macromonomer which is in the range of from 5 to 99 mol %; c is a molar percentage of the macromonomer which is in the range of from 0 to 2 mol %; and d is a molar percentage of the macromonomer which is in the range of from 0 to 2 mol %; with the proviso that c and d are not both 0 mol %. | 11-05-2009 |
20110190467 | Biological Polysiloxanes - The present invention relates to a macromonomer having a polydimethylsiloxane backbone that has a mol % dimethyl siloxanes, b mol % siloxanes substituted with -K-RIM, c mol % siloxanes substituted with -K-RIM-Z and d mol % siloxanes substituted with -L-Z, and in which the terminal siloxane groups are tri-substituted with R, wherein RIM is a refractive index modifying group; Z is a free radically polymerisable group; K is a spacer group; L is optional and is a spacer group; each R is independently selected from an RIM, a lower alkyl group, hydrogen or Z; and a is a molar percentage of the macromonomer which is in the range of from 0 to 95 mol %; b is a molar percentage of the macromonomer which is in the range of from 5 to 99 mol %; c is a molar percentage of the macromonomer which is in the range of from 0 to 2 mol %; and d is a molar percentage of the macromonomer which is in the range of from 0 to 2 mol %; with the proviso that c and d are not both 0 mol %. | 08-04-2011 |
Patent application number | Description | Published |
20080255139 | Use Of 4- (4-Methylpiperazin-1-Ylmethyl)-N-[4-Methyl-3-(4-(Pyridin-3-Yl)Pyrimidin-2-Ylamino)Phenyl]-Benzamide to Inhibit the Tyrosine Kinase Receptor C-Fms - This invention relates to the use of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide (also known as imatinib, gleevec, glivec, cgp57148b or STI571), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of c-fms-associated diseases including; choriocarcinoma, malignant histiocytosis, embryonal carcinoma, endometrial carcinoma, brain microglial tumours, sarcoidosis, microglial cell involvement in normal and variant Creutzfeld-Jacob disease, and amyotrophic lateral sclerosis. | 10-16-2008 |
20100184779 | METHOD FOR OPTIMIZING THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH ABL TYROSINE KINASE INHIBITORS - The present invention relates to a method for evaluating patients to help optimizing the treatment of chronic myeloid leukemia (CML) in a human patient population. More specifically, the method comprises the steps of (a) determining the OCT-1 Activity in pre-therapy blood of a warm-blooded animal suffering from CML, and (b) administering a daily dose between about 500 and 1200 mg of Imatinib mesylate to the warm-blooded animal suffering from CML showing an OCT-1 Activity corresponding to Imatinib intracellular concentration to below about 6.0 to 10.0 ng/200,000 cells, especially about 8.0 to 8.5 ng/200,000 cells. | 07-22-2010 |
20110224224 | Method of Optimizing the Treatment of Philadelphia-Positive Leukemia with Imatinib Mesylate - The present invention relates to a method of treating Philadelphia-positive leukemia (Ph+ leukemia), in a particular chronic myeloid leukemia (CML), in a human patient population. More specifically, the present invention pertains to a method of treating Ph+ leukemia, such as CML or Ph+ ALL, in a human patient suffering from Ph+ leukemia comprising the steps of | 09-15-2011 |
Patent application number | Description | Published |
20120244116 | METHOD OF TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE LEUKAEMIA - The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib. In some embodiments, the agent binds to a receptor involved in signalling by at least one of IL-3, G-CSF and GM-CSF. In some embodiments, the agent is a mutein selected from the group consisting of IL-3 muteins, G-CSF muteins and GM-CSF muteins. In some embodiments, the mutein is an IL-3 mutein. In some embodiments, the agent is a soluble receptor which is capable of binding to IL-3. | 09-27-2012 |
20150093355 | METHOD OF TREATMENT OF PHILADELPHIA CHROMOSOME POSITIVE LEUKEMIA - The invention provides a method for the treatment of Ph+ leukemia in a patient comprising administering to the patient (i) a BCR-ABL tyrosine kinase inhibitor, and (ii) an agent which selectively binds to a cell surface receptor expressed on Ph+ leukemic stem cells. The invention further provides for the use of (i) and (ii) in, or in the manufacture of a medicament for, the treatment of Ph+ leukemia in a patient; and a composition for the treatment of Ph+ leukemia in a patient comprising (i) and (ii); and kits comprising (i) and (ii). In some embodiments, the tyrosine kinase inhibitor is or is not imatinib; or is selected from the group consisting of dasatinib, nilotinib, bosutinib, axitinib, cediranib, crizotinib, damnacanthal, gefitinib, lapatinib, lestaurtinib, neratinib, semaxanib, sunitinib, toceranib, tyrphostins, vandetanib, vatalanib, INNO-406, AP24534, XL228, PHA-739358, MK-0457, SGX393 and DC2036; or is selected from the group consisting of dasatinib and nilotinib. In some embodiments, the agent binds to a receptor involved in signalling by at least one of IL-3, G-CSF and GM-CSF. In some embodiments, the agent is a mutein selected from the group consisting of IL-3 muteins, G-CSF muteins and GM-CSF muteins. In some embodiments, the mutein is an IL-3 mutein. In some embodiments, the agent is a soluble receptor which is capable of binding to IL-3. | 04-02-2015 |